A Randomized Double-Blinded Crossover Trial to Define the ECG Effects of Mipomersen (ISIS 301012) Using a Therapeutic and Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial.
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2016
At a glance
- Drugs Mipomersen (Primary) ; Mipomersen (Primary)
- Indications Atherosclerosis; Bacterial infections; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- 09 Dec 2015 Results published in the European Journal of Clinical Pharmacology
- 16 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 16 Jul 2010 Actual patient number is 60 as reported by ClinicalTrials.gov.